-
2
-
-
84859919751
-
Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
-
Rajkumar SV. Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Am J Hematol 2012; 87: 453-454.
-
(2012)
Am J Hematol
, vol.87
, pp. 453-454
-
-
Rajkumar, S.V.1
-
3
-
-
0023849455
-
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
-
Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
-
(1988)
Nature
, vol.332
, pp. 83-85
-
-
Kawano, M.1
Hirano, T.2
Matsuda, T.3
Taga, T.4
Horii, Y.5
Iwato, K.6
-
4
-
-
0024503249
-
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
-
Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517-526.
-
(1989)
Blood
, vol.73
, pp. 517-526
-
-
Klein, B.1
Zhang, X.G.2
Jourdan, M.3
Content, J.4
Houssiau, F.5
Aarden, L.6
-
5
-
-
73149112786
-
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma
-
Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009; 15: 7144-7152.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7144-7152
-
-
Fulciniti, M.1
Hideshima, T.2
Vermot-Desroches, C.3
Pozzi, S.4
Nanjappa, P.5
Shen, Z.6
-
6
-
-
84877772107
-
Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma
-
Chari A, Pri-Chen H, Jagannath S. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk 2013; 13: 333-337.
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. 333-337
-
-
Chari, A.1
Pri-Chen, H.2
Jagannath, S.3
-
7
-
-
84888393068
-
(18)F-FDG-PET/CT imaging in an IL-6-and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib
-
Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F et al. (18)F-FDG-PET/CT imaging in an IL-6-and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J 2013; 3: e165.
-
(2013)
Blood Cancer J
, vol.3
, pp. e165
-
-
Duncan, K.1
Rosean, T.R.2
Tompkins, V.S.3
Olivier, A.4
Sompallae, R.5
Zhan, F.6
-
8
-
-
24744440161
-
Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice
-
Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM et al. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res 2005; 65: 7644-7652.
-
(2005)
Cancer Res
, vol.65
, pp. 7644-7652
-
-
Park, S.S.1
Shaffer, A.L.2
Kim, J.S.3
Dubois, W.4
Potter, M.5
Staudt, L.M.6
-
9
-
-
0030929261
-
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice
-
Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151: 689-696.
-
(1997)
Am J Pathol
, vol.151
, pp. 689-696
-
-
Lattanzio, G.1
Libert, C.2
Aquilina, M.3
Cappelletti, M.4
Ciliberto, G.5
Musiani, P.6
-
10
-
-
0026643286
-
Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: Inhibition by indomethacin
-
Shacter E, Arzadon GK, Williams J. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin. Blood 1992; 80: 194-202.
-
(1992)
Blood
, vol.80
, pp. 194-202
-
-
Shacter, E.1
Arzadon, G.K.2
Williams, J.3
-
11
-
-
0030200982
-
Distinct tumorigenic potential of abl and raf in B cell neoplasia: Abl activates the IL-6 signaling pathway
-
Hilbert DM, Migone TS, Kopf M, Leonard WJ, Rudikoff S. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 1996; 5: 81-89.
-
(1996)
Immunity
, vol.5
, pp. 81-89
-
-
Hilbert, D.M.1
Migone, T.S.2
Kopf, M.3
Leonard, W.J.4
Rudikoff, S.5
-
12
-
-
84868597426
-
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
-
Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA, Novak AJ et al. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood 2012; 120: 3774-3782.
-
(2012)
Blood
, vol.120
, pp. 3774-3782
-
-
Hodge, L.S.1
Ziesmer, S.C.2
Yang, Z.Z.3
Secreto, F.J.4
Gertz, M.A.5
Novak, A.J.6
-
13
-
-
84896494013
-
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
-
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014; 26: 54-74.
-
(2014)
Semin Immunol
, vol.26
, pp. 54-74
-
-
Taniguchi, K.1
Karin, M.2
-
14
-
-
67049114114
-
A monoclonal gammopathy precedes multiple myeloma in most patients
-
Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
-
(2009)
Blood
, vol.113
, pp. 5418-5422
-
-
Weiss, B.M.1
Abadie, J.2
Verma, P.3
Howard, R.S.4
Kuehl, W.M.5
-
15
-
-
84865585752
-
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
-
Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
-
(2012)
Blood
, vol.120
, pp. 1877-1887
-
-
Tai, Y.T.1
Chang, B.Y.2
Kong, S.Y.3
Fulciniti, M.4
Yang, G.5
Calle, Y.6
|